| | |
PD-L1 expression
|
P
|
PIK3CA
|
P
|
MSI/dMMR
|
P
|
|---|
|
Total
|
Positive
|
Negative
| |
MT
|
WT
| |
Positive
|
Negative
| |
|---|
|
N = 64 (%)
|
n = 23 (35.9%)
|
n = 41 (64.1%)
| |
n = 8 (12.5%)
|
n = 56 (87.5%)
| |
n = 11 (17.2%)
|
n = 53 (82.8%)
| |
|---|
|
Sex
| | | |
0.545
| | |
0.019
| | |
1.000
|
|
Male
|
60 (93.8)
|
21 (91.3)
|
39 (95.1)
| |
6 (75.0)
|
54 (96.4)
| |
11 (100)
|
49 (92.5)
| |
|
Female
|
4 (6.2)
|
2 (8.7)
|
2 (4.9)
| |
2 (25.0)
|
2 (3.6)
| |
0 (0.0)
|
4 (7.5)
| |
|
Age (years)
| | | |
0.291
| | |
0.043
| | |
0.039
|
|
≤ 60
|
26 (40.6)
|
7 (30.4)
|
19 (46.3)
| |
6 (75.0)
|
20 (35.7)
| |
8 (72.7)
|
18 (34.0)
| |
|
> 60
|
38 (59.4)
|
16 (69.6)
|
22 (53.7)
| |
2 (25.0)
|
36 (64.3)
| |
3 (27.3)
|
35 (66.0)
| |
|
Smoking
| | | |
0.048
| | |
0.850
| | |
0.322
|
|
Light
|
34 (53.1)
|
16 (69.6)
|
18 (4.9)
| |
4 (50.0)
|
30 (53.6)
| |
4 (36.4)
|
30 (56.6)
| |
|
Heavy
|
30 (46.9)
|
7 (30.4)
|
23 (56.1)
| |
4 (50.0)
|
26 (46.4)
| |
7 (63.6)
|
23 (43.4)
| |
|
Alcohol
| | | |
0.728
| | |
0.564
| | |
0.176
|
|
Light
|
26 (40.6)
|
10 (43.5)
|
16 (39.0)
| |
4 (50.0)
|
22 (39.3)
| |
2 (18.2)
|
24 (45.3)
| |
|
Heavy
|
38 (59.4)
|
13 (56.5)
|
25 (61.0)
| |
4 (50.0)
|
34 (60.7)
| |
9 (81.8)
|
29 (54.7)
| |
|
Location
| | | |
0.216
| | |
0.179
| | |
1.000
|
|
Upper/Middle
|
45 (70.3)
|
14 (60.9)
|
31 (48.4)
| |
4 (50.0)
|
41 (73.2)
| |
8 (72.7)
|
37 (69.8)
| |
|
Lower
|
19 (29.7)
|
9 (39.1)
|
10 (15.6)
| |
4 (50.0)
|
15 (26.8)
| |
3 (27.3)
|
16 (30.2)
| |
|
Differentiation
| | | |
0.291
| | |
0.253
| | |
0.039
|
|
WD
|
26 (40.6)
|
7 (30.4)
|
19 (46.3)
| |
5 (62.5)
|
21 (37.5)
| |
8 (72.7)
|
18 (34.0)
| |
|
MD/PD
|
38 (59.4)
|
16 (69.6)
|
22 (53.7)
| |
3 (37.5)
|
35 (62.5)
| |
3 (27.3)
|
35 (66.0)
| |
|
T category
| | | |
0.622
| | |
0.282
| | |
0.428
|
|
T1-T2
|
36 (56.2)
|
12 (52.2)
|
24 (58.5)
| |
3 (37.5)
|
33 (58.9)
| |
5 (45.5)
|
31 (58.5)
| |
|
T3-T4
|
28 (43.8)
|
11 (47.8)
|
17 (41.5)
| |
5 (62.5)
|
23 (41.1)
| |
6 (54.5)
|
22 (41.5)
| |
|
N category
| | | |
0.282
| | |
0.498
| | |
0.247
|
|
N0
|
39 (60.9)
|
12 (52.2)
|
27 (65.9)
| |
4 (50.0)
|
35 (62.5)
| |
5 (45.5)
|
34 (64.2)
| |
|
N1–3
|
25 (39.1)
|
11 (47.8)
|
14 (34.1)
| |
4 (50.0)
|
21 (37.5)
| |
6 (54.5)
|
19 (35.8)
| |
|
AJCC stage
| | | |
0.459
| | |
0.435
| | |
0.199
|
|
I-II
|
40 (62.5)
|
13 (56.5)
|
27 (65.9)
| |
4 (50.0)
|
36 (64.3)
| |
5 (45.5)
|
35 (66.0)
| |
|
III-IV
|
24 (37.5)
|
10 (43.5)
|
14 (34.1)
| |
4 (50.0)
|
20 (35.7)
| |
6 (54.5)
|
18 (34.0)
| |
|
LI
| | | |
0.291
| | |
0.456
| | |
1.000
|
|
Absent
|
26 (40.6)
|
7 (30.4)
|
19 (46.3)
| |
2 (25.0)
|
24 (42.9)
| |
4 (36.4)
|
22 (41.5)
| |
|
Present
|
38 (59.4)
|
16 (69.6)
|
22 (53.7)
| |
6 (75.0)
|
32 (57.1)
| |
7 (63.6)
|
31 (58.5)
| |
|
VI
| | | |
0.648
| | |
0.683
| | |
1.000
|
|
Absent
|
44 (68.8)
|
15 (65.2)
|
29 (70.7)
| |
5 (62.5)
|
39 (69.6)
| |
8 (72.7)
|
36 (67.9)
| |
|
Present
|
20 (31.2)
|
8 (34.8)
|
12 (29.3)
| |
3 (37.5)
|
17 (30.4)
| |
3 (27.3)
|
17 (32.1)
| |
|
PI
| | | |
0.755
| | |
0.196
| | |
1.000
|
|
Absent
|
51 (79.7)
|
19 (82.6)
|
32 (78.0)
| |
5 (62.5)
|
46 (82.1)
| |
9 (81.8)
|
42 (79.2)
| |
|
Present
|
13 (20.3)
|
4 (17.4)
|
9 (22.0)
| |
3 (37.5)
|
10 (17.9)
| |
2 (18.2)
|
11 (20.8)
| |
|
Skip lesion
| | | |
0.345
| | |
0.673
| | |
0.431
|
|
Absent
|
50 (78.1)
|
20 (87.0)
|
30 (73.2)
| |
7 (87.5)
|
43 (76.8)
| |
10 (90.9)
|
40 (75.5)
| |
|
Present
|
14 (21.9)
|
3 (13.0)
|
11 (26.8)
| |
1 (12.5)
|
13 (23.2)
| |
1 (0.1)
|
13 (24.5)
| |
|
Dysplasia
| | | |
0.610
| | |
0.060
| | |
0.058
|
|
Absent
|
36 (56.2)
|
14 (60.9)
|
22 (53.7)
| |
7 (87.5)
|
29 (51.8)
| |
9 (81.8)
|
27 (50.9)
| |
|
Present
|
28 (43.8)
|
9 (39.1)
|
19 (46.3)
| |
1 (12.5)
|
27 (48.2)
| |
2 (18.2)
|
26 (49.1)
| |
|
TIL density
| | | |
0.170
| | |
0.320
| | |
0.395
|
|
Low
|
22 (34.4)
|
5 (21.7)
|
17 (41.5)
| |
4 (50.0)
|
18 (32.1)
| |
5 (45.5)
|
17 (32.1)
| |
|
High
|
42 (65.6)
|
18 (78.3)
|
24 (58.5)
| |
4 (50.0)
|
38 (67.9)
| |
6 (54.5)
|
36 (67.9)
| |
|
HPV
| | | |
1.000
| | |
1.000
| | |
1.000
|
|
Negative
|
63 (98.4)
|
23 (100)
|
40 (97.6)
| |
8 (100)
|
55 (98.2)
| |
11 (100)
|
52 (98.1)
| |
|
Positive
|
1 (1.6)
|
0 (0.0)
|
1 (2.4)
| |
0 (0.0)
|
1 (1.8)
| |
0 (0.0)
|
1 (1.9)
| |
|
MSI/MMR
| | | |
0.732
| | |
0.531
| | |
–
|
|
MSS/pMMR
|
53 (82.8)
|
20 (87.0)
|
33 (80.5)
| |
6 (75.0)
|
47 (83.9)
| |
–
|
–
| |
|
MSI/dMMR
|
11 (17.2)
|
3 (13.0)
|
8 (19.5)
| |
2 (25.0)
|
9 (16.1)
| |
–
|
–
| |
|
PIK3CA status
| | | |
0.700
| | | | | | |
|
Wildtype
|
56 (87.5)
|
21 (91.3)
|
35 (85.4)
| |
–
|
–
| |
–
|
–
| |
|
Mutated
|
8 (12.5)
|
2 (8.7)
|
6 (14.6)
| |
–
|
–
| |
–
|
–
| |
- ESCC esophageal squamous cell carcinoma, PD-L1 programmed death ligand-1, MT mutated, WT wild type, MSI microsatellite instability, pMMR patent mismatch repair, dMMR deficient mismatch repair, AJCC Amedican Joint Committee on Cancer 8th edition, WD well-differentiation, MD moderately-differentiation, PD poorly-differentiation, LI lymphatic invasion, VI vascular invasion, PI perineural invasion, TIL tumor-infiltrating lymphocyte, HPV human papillomavirus
